Treatment Sequence May Impact Pancreatic Cancer Survival Treatment Sequence May Impact Pancreatic Cancer Survival
The sequence of systemic therapies for advanced pancreatic ductal adenocarcinoma can affect overall patient survival, a new analysis suggests.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
FAPI-PET outperforms FDG-PET in diagnosing pancreatic cancer
F-18 FAPI-PET/CT is superior to F-18 FDG-PET/CT for diagnosing and staging patients with pancreatic cancer, according to a study published January 4 in the Journal of Nuclear Medicine.
In a clinical trial, F-18 FAPI-04 radiotracer performed better than F-18 FDG in identifying primary tumors, lymph node metastasis, and distant metastases in patients with pancreatic ductal adenocarcinoma (PDAC). The findings suggest that F-18 FAPI-04 PET/CT offers a new method for identifying malignancies in these patients, according to first author Xiang Li, PhD, of Zhejiang University in Hangzhou, China, and colleagues.
“In the future,...
Source: AuntMinnie.com Headlines - January 5, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Molecular Imaging Radiation Oncology/Therapy Nuclear Radiology Source Type: news
Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers
FRIDAY, Dec. 22, 2023 -- Higher ultra-processed food (UPF) consumption is associated with a greater risk for head and neck cancer (HNC) and esophageal adenocarcinoma (OAC), according to a study published online Nov. 22 in the European Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2023 Category: Pharmaceuticals Source Type: news
Long-Term Organ Preservation in Rectal Cancer Is Possible Long-Term Organ Preservation in Rectal Cancer Is Possible
Long-term data from the OPRA trial show organ preservation at 5 years in about half of patients with stage II/III rectal adenocarcinoma who received total neoadjuvant therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer
Adding pembrolizumab to chemotherapy had significant benefits in patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval marks seventh gastrointestinal cancer indication for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Road to RSNA 2023: AI Preview
Welcome to the first installment of this year’s Road to RSNA preview of the RSNA 2023 meeting. We’re once again providing a modality-by-modality overview of select scientific presentations to serve as your guide to events at McCormick Place.
Our journey along the Road to RSNA begins again with our preview of AI, a topic that has dominated the annual meeting for the past seven years. Research on AI topics will be omnipresent, featuring both in dedicated sessions as well as throughout the scientific program. In fact, it’s hard to find a scientific session without at least one AI-related presentation.
AI’s capabilit...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Erik L. Ridley Tags: 2023 Source Type: news
20-year study shows that lung cancer screening boosts survival rates
Diagnosing early-stage lung cancer with low-dose CT (LDCT) translates to a 20-year survival rate of 81%, according to a large-scale, 20-year international study published November 7 in Radiology.And this survival rate is even higher among those diagnosed with Stage 1 disease, at 95%, lead author Claudia Henschke, MD, PhD, of the Icahn School of Medicine at Mount Sinai in New York City said in an RSNA statement."[Our study] is the first time that 20-year survival rates from annual screening have been reported," she said. "This 20-year survival rate of 81% is the estimated cure rate of all participants with lung cancers diag...
Source: AuntMinnie.com Headlines - November 7, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News Subspecialties CT Chest Radiology Source Type: news
ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
WEDNESDAY, Oct. 25, 2023 -- For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2023 Category: Pharmaceuticals Source Type: news
Risk for Esophageal Adenocarcinoma Not Increased With Nonerosive GERD
WEDNESDAY, Sept. 20, 2023 -- Patients with nonerosive gastroesophageal reflux disease (GERD) do not have an increased risk for esophageal adenocarcinoma compared with the general population, according to a study published online Sept. 13 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news
Non-Erosive GERD May Not Increase Risk of Esophageal Cancer
(MedPage Today) -- Patients with non-erosive gastroesophageal reflux disease (GERD) appear to have a similar incidence of esophageal adenocarcinoma as the general population, according to a large Nordic population-based cohort study with up to... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 18, 2023 Category: Gastroenterology Source Type: news
Methylation Score Can ID Risk for Cervical Adenocarcinomas
WEDNESDAY, Sept. 13, 2023 -- A methylation score, composed of the average methylation percentage across 35 CpG sites in the L2/L1 open reading frames of human papillomavirus (HPV)16, 18, and 45, and two human loci, can identify the risk for cervical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2023 Category: Pharmaceuticals Source Type: news
Large-Scale Investigation Supports Modified Classification System for Pulmonary Adenocarcinomas
A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 11, 2023 Category: Pharmaceuticals Tags: TRI SVY Source Type: news
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care
(MedPage Today) -- An intratumoral drug-releasing microdevice implanted in glioma patients can measure the drug's antitumor effects and could potentially help guide treatment, early data suggest. (Brigham and Women's Hospital, Science Translational... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 7, 2023 Category: Hematology Source Type: news
